We can’t show the full text here under this license. Use the link below to read it at the source.
The efficacy of valproate in acute mania, bipolar depression and maintenance therapy for bipolar disorder: an overview of systematic reviews with meta-analyses
Valproate’s effectiveness in treating sudden mania, bipolar depression, and long-term bipolar disorder management: a summary of reviews
AI simplified
Abstract
Valproate demonstrated a significantly better response than placebo for acute mania with a relative risk of 1.42.
- In acute mania, valproate outperformed placebo in two high-quality systematic reviews, with relative risk estimates indicating improved response.
- No significant differences were observed between valproate and lithium across most outcomes.
- For bipolar depression, valproate was more effective than placebo in reducing depressive symptoms and achieving remission.
- Valproate had superior efficacy compared to aripiprazole, ziprasidone, and agomelatine in bipolar depression treatment.
- In maintenance treatment, valproate was superior to placebo in preventing relapse of mood episodes.
- No significant differences were found when comparing valproate with lithium, olanzapine, or lamotrigine in maintenance treatment.
AI simplified
Key numbers
1.42
Increase in Response Rate
Relative risk for response in acute mania treatment
2.80
Increase in Remission Rate
Odds ratio for remission in bipolar depression treatment
0.63
Decrease in Relapse Risk
Relative risk for relapse prevention in maintenance treatment